Eye diseases such as diabetic retinopathy and age-related macular degeneration are among the leading causes of irreversible vision loss and blindness worldwide. Currently, gene therapy can be administered to treat these conditions — but this requires an injection. Now researchers report in the journal ACS Applied Materials & Interfaces a new way to deliver the treatment topically, without a needle.
The rear part of the eye is where conditions such as proliferative diabetic retinopathy and age-related macular degeneration develop. And they involve a substance called vascular endothelial growth factor, which stimulates the growth of blood vessels. Scientists have been trying to inhibit the growth factor using gene therapy, but delivering drugs to the back of the eye currently requires an injection. Not surprisingly, few patients opt for this type of treatment. Gang Wei and colleagues wanted to find a noninvasive approach.
The researchers developed a gene delivery system with a peptide called penetratin, which has shown good permeability in the eye, and a synthetic polymer called poly(amidoamine) that has previously been used in drug delivery. Testing on rats showed that the complex, when applied as an eye drop, rapidly moved from the eye’s surface to its rear inner lining. It remained in the retina for more than eight hours — enough time for a model gene to be expressed. The findings demonstrate the method’s potential for delivering gene therapy to treat several eye diseases, the researchers say.
The Latest on: Gene therapy in a droplet
via Google News
The Latest on: Gene therapy in a droplet
- Is Now A Good Time To Buy BioMarin Stock?on January 22, 2021 at 4:58 am
Shares in this biotech company are down considerably from where they were this summer, but the stock looks ready to take off again.
- Chinese scientists develop gene therapy which could delay ageingon January 20, 2021 at 7:30 pm
Scientists in Beijing have developed a new gene therapy which can reverse some of the effects of ageing in mice and extend their lifespans, findings which may one day contribute to similar treatment ...
- Taysha Gene Therapies Announces New cGMP Gene Therapy Manufacturing Facilityon January 18, 2021 at 12:14 am
Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the ...
- Silicon Valley’s share of venture capital expected to drop below 20% for the first time this yearon January 14, 2021 at 6:39 am
Founded in 2019, the 250-person company has an ambitious goal of both repairing cells in the body (gene therapy), and replacing damaged cells (cell therapy). Sana is also aiming to innovate how gene ...
- Moncef Slaoui to step down from Operation Warp Speed in a month — reporton January 13, 2021 at 2:49 am
Moncef Slaoui’s tumultuous reign as chief of Operation Warp Speed is coming to an end. The former GlaxoSmithKline vaccine exec has submitted his resignation at the request of the incoming Biden ...
- This $850,000 Gene Therapy Injection Is the Most Expensive One-Time Dose Medicine Ever Madeon January 11, 2021 at 4:00 pm
Despite the small drop in price, Luxturna is still significantly more expensive than almost every other medication on the global market, including two separate gene therapy treatments approved ...
- Novartis brings BeiGene's promising checkpoint inhibitor into the fold, but what about highly touted spartalizumab?on January 11, 2021 at 2:29 pm
Arriving on the Chinese market among a wave of PD-1 checkpoint inhibitors in late 2019, BeiGene's tislelizumab has earned laurels for its outstanding data and broad pipeline. Now, Novartis has signed ...
- Translate Bio targets Q2 data drop on nebulized mRNA therapyon January 11, 2021 at 12:25 pm
Vertex’s triple combination therapy cystic fibrosis drug Trikafta is limited to the 90% of patients with at least one F508del mutation in the CFTR gene.
- Sarepta Stock Gains as CEO Explains What Went Wrong With Gene-Therapy Trialon January 11, 2021 at 12:14 pm
The study’s failure to show a statistically significant strength improvement in children who were treated caused Sarepta stock (ticker: SRPT) to drop by ... to get the gene therapy were much ...
- Sarepta Sinks on Disappointing Gene-Therapy Study Resultson January 8, 2021 at 4:10 pm
Sarepta Therapeutics (SRPT) - Get Report shares plunged on Friday, losing nearly half their value after a key gene-therapy study produced disappointing results. Shares of Sarepta plunged 50.45% ...
via Bing News